Dare Bioscience, Inc. - Common Stock (DARE)
Frequently Asked Questions About Dare Bioscience, Inc. - Common Stock (DARE)
Has Dare Bioscience, Inc. received any FDA approvals?
Yes, Dare Bioscience, Inc. has received FDA approval for its lead product, XACIATO™, which was approved in 2021 for treating bacterial vaginosis. This milestone represents a significant achievement in the company's mission to improve women's health.
How can investors learn more about Dare Bioscience, Inc.?
Investors can learn more about Dare Bioscience, Inc. by visiting the company's official website, reviewing its most recent financial reports, corporate presentations, and press releases. Additionally, the company engages in investor relations initiatives to provide updates and insights into its business operations.
How does Dare Bioscience, Inc. differentiate itself from competitors?
Dare Bioscience, Inc. differentiates itself through its unique focus on women's health and its innovative drug delivery technology platform. This allows the company to develop products that address specific reproductive health needs, establishing a niche in a largely underserved market.
How does Dare Bioscience, Inc. fund its operations?
Dare Bioscience, Inc. funds its operations through a combination of equity financing, grants, and strategic partnerships. The company may also seek additional funding through collaborations with larger pharmaceutical companies or public offering of its common stock.
How does the company ensure drug safety?
Dare Bioscience, Inc. ensures drug safety through rigorous preclinical and clinical testing, adhering to regulatory guidelines from the FDA and other health authorities. The company conducts comprehensive studies to evaluate safety, efficacy, and tolerability before any product is brought to market.
Is Dare Bioscience involved in partnerships or collaborations?
Yes, Dare Bioscience, Inc. actively seeks partnerships and collaborations with other biotech and pharmaceutical companies to enhance its research capabilities and accelerate the development of its products. These alliances can provide access to additional resources and expertise in women's health.
What are some of the products developed by Dare Bioscience?
Dare Bioscience has developed several innovative products including XACIATO™, a vaginal gel for the treatment of bacterial vaginosis, and is also working on a range of product candidates related to contraception and menopausal health, among others.
What are the clinical trials currently underway for Dare Bioscience's products?
Dare Bioscience is actively conducting clinical trials for several of its product candidates, including ongoing studies to evaluate the safety and efficacy of innovative therapies related to contraception and menopause. Details about specific trials can be found on clinical trial registries.
What are the long-term goals of Dare Bioscience, Inc.?
The long-term goals of Dare Bioscience, Inc. include expanding its portfolio of innovative women's health products, achieving successful market penetration, and ultimately improving the quality of life for women through the delivery of effective therapeutic solutions.
What challenges does Dare Bioscience, Inc. face?
Like many biopharmaceutical companies, Dare Bioscience, Inc. faces several challenges, including regulatory hurdles, competition from other companies in the women's health space, and the need for significant capital for research and development activities.
What does Dare Bioscience, Inc. do?
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutic products for women's health. The company's research emphasizes novel drug delivery technologies and formulations to address unmet medical needs in areas such as contraception, menopause, and sexual health.
What is Dare Bioscience's strategy for growth?
Dare Bioscience's strategy for growth involves leveraging its proprietary drug delivery technologies, expanding its clinical pipeline, and forming strategic partnerships to accelerate the development and commercialization of its products in the women's health sector.
What is the focus area of Dare Bioscience, Inc.?
The primary focus area of Dare Bioscience, Inc. is women's health. The company aims to develop safe and effective treatments that address various issues related to reproductive health, menopause, and sexual wellbeing, utilizing advanced drug delivery methods.
What is the ticker symbol for Dare Bioscience, Inc.?
The ticker symbol for Dare Bioscience, Inc. is DARE, and it trades on the Nasdaq stock exchange. Investors can track the performance of the company's common stock using this symbol.
What is the vision of Dare Bioscience, Inc.?
The vision of Dare Bioscience, Inc. is to be a leader in women's health by developing transformative therapies that meet the unique needs of women. The company is committed to making a positive impact on the lives of women through innovation and enhanced access to healthcare solutions.
What market need does Dare Bioscience address?
Dare Bioscience, Inc. addresses a significant market need for effective and innovative solutions in women's health, particularly in areas where there has been limited advancement. This includes contraceptive methods, treatments for menopause-related symptoms, and therapies for common reproductive health issues.
When was Dare Bioscience, Inc. founded?
Dare Bioscience, Inc. was founded in 2015. Since its inception, the company has focused on developing novel women’s health products through its proprietary drug delivery technologies and strategic collaborations.
Where is Dare Bioscience, Inc. headquartered?
Dare Bioscience, Inc. is headquartered in San Diego, California. The company operates in a vibrant biotech ecosystem that provides access to skilled talent, resources, and partnerships in the life sciences sector.
Who are the key executives at Dare Bioscience, Inc.?
The key executives at Dare Bioscience, Inc. include the CEO, Dr. Dawn M. Buse, and the Chief Financial Officer, Louisa K. R. McClain. Their leadership is focused on advancing the company's innovative pipeline and establishing strategic partnerships.
What is the current price of Dare Bioscience, Inc. - Common Stock?
The current price of Dare Bioscience, Inc. - Common Stock is 2.910
When was Dare Bioscience, Inc. - Common Stock last traded?
The last trade of Dare Bioscience, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Dare Bioscience, Inc. - Common Stock?
The market capitalization of Dare Bioscience, Inc. - Common Stock is 205.22M
How many shares of Dare Bioscience, Inc. - Common Stock are outstanding?
Dare Bioscience, Inc. - Common Stock has 70.52M shares outstanding.